| Home Market Dynamics Macro Trends Sector Trends Company Insights AI Investing Strategies Sign Up Login |
Sector: Biotechnology
| Gilead Sciences is focusing on the ongoing development and enhancement of its therapeutic products, such as Yescarta, in response to evolving market needs, and the growth of its HIV drug portfolio, which is crucial for future expansion. However, the company faces a mixed performance in product lines as sales of its HIV therapies are strong, while the cell-therapy segment shows declining results. This duality suggests a need for strategic adjustments to maximize overall portfolio performance. The emphasis on innovative product development and meeting market demands positions Gilead favorably for sustained growth. |
| The price action of Gilead Sciences (GILD) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The trend sentiment at 1.9 is very bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next. There is no clear direction for GILD since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 1.2, and the negative at -1.2 on 2026-02-10. The forces of Sentiment towards Fundamentals (2.3), Stock Price Trend (1.9), Option Sentiment (1.5), and Valuation Sentiment (1.4) will drive up the price. The forces of Price Level Sentiment (-0.5), Sector Price Trend (-0.5), and Market Risk Appetite (-6.5) will drive down the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
Sign up to reveice notifications on Market Movers
| GILD | ||||||||||||||
| Date | Attention | Price | StdDev | Price Level | Change | 10 Day Trend | Trend Sentiment | Hourly Trend Sentiment | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-10 | 0%(0%) | 147.23 | 6.76% | 75 | -2.93% | 0.41% | 1.9 | -0.8 | 0.9% | -0 | Long | 65% | 2.3 | -4.3 |
| 2026-02-09 | 0%(0%) | 151.68 | 6.7% | 89 | -0.54% | 0.98% | 3.3 | 0.1 | 0.7% | 0.5 | Long | 65% | 2.3 | -1 |
| 2026-02-08 | 0%(0%) | 3.8 | 0.1 | -0.3 | 1.4 | -1 | ||||||||
| 2026-02-07 | 0%(0%) | 3.8 | 0.1 | -0 | 1.8 | -1 | ||||||||
| 2026-02-06 | 0%(0%) | 152.5 | 6.56% | 95 | 2.1% | 1.13% | 3.8 | 0.5 | 1.4% | 0.1 | Long | 70% | 1.7 | -1 |
| 2026-02-05 | 0%(0%) | 149.37 | 6.38% | 93 | 2.15% | 1.36% | 3.6 | 0.3 | 1.5% | -0.2 | Long | 55% | 1.4 | -1 |
| 2026-02-04 | 0%(0%) | 146.23 | 6.09% | 91 | 2.06% | 1.23% | 3.1 | 0.4 | 0.9% | 0.1 | Long | 55% | 1.1 | -1 |
| 2026-02-03 | 0%(0%) | 143.28 | 5.95% | 88 | 0.27% | 1.39% | 2.7 | -0.2 | 1.1% | -0.3 | Long | 65% | 1.1 | -1 |
| 2026-02-02 | 0%(0%) | 142.89 | 5.86% | 91 | 0.66% | 1.34% | 2.9 | 0.4 | 0.9% | -0.1 | Long | 55% | 1.4 | -1 |
| 2026-02-01 | 0%(0%) | 3.1 | 0.4 | 0 | 2.1 | -1 | ||||||||
| Long is the preferred trading strategy with 65% chance of being right. Both trend sentiment and hourly trend are very strong. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | ||||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | ||||||||||||||
| 2026-02-10 22:48:14 Weak FY26 guidance suggests challenges ahead for Gilead, impacting investor sentiment negatively. |
| 2026-02-10 22:48:14 The slip in Gilead's stock price following earnings highlights investor reaction to financial guidance. |
| 2026-02-10 22:48:14 The focus on Gilead Sciences' Q4 earnings report indicates concerns over the company's financial performance. |
| 2026-02-10 17:48:45 HIV drug sales are doing well while cell-therapy portfolio sales are decreasing, indicating mixed results in product lines. |
| 2026-02-10 17:48:45 Despite earnings surprises in certain areas, the overall stock performance is declining due to unfavorable forecasts and falling sales in key products. |
| 2026-02-10 17:48:45 Gilead's earnings report indicates a miss on revenue and profit forecasts, leading to negative sentiment despite some product successes. |
| 2026-02-10 17:09:21 Despite positive earnings, fluctuations in Gilead's stock price indicate market volatility and investor caution regarding future forecasts. |
| 2026-02-10 17:09:21 Gilead's strong product lineup, including Biktarvy, positions it favorably in the competitive landscape of the pharmaceutical industry. |
| 2026-02-10 17:09:21 The recent increase in Gilead's quarterly dividend reflects the company's commitment to shareholder returns and confidence in its ongoing profitability. |
| 2026-02-10 17:09:21 Investors see Gilead as a strong buy due to its favorable stock valuation, promising dividends, and growth potential in the pharmaceutical market. |
| 2026-02-10 17:09:21 Gilead Sciences has shown strong financial performance, surpassing analyst expectations in recent quarterly reports and maintaining a positive growth trajectory. |